MEHISDIN-P

This brand name is authorized in Singapore

Active ingredients

The drug MEHISDIN-P contains a combination of these active pharmaceutical ingredients (APIs):

1 Dexchlorpheniramine
UNII V1Q0O9OJ9Z - CHLORPHENIRAMINE MALEATE

Dexchlorpheniramine, the d-isomer of the racemic compound chlorpheniramine, is two times more active than chlorpheniramine. Dexchlorpheniramine does not prevent the release of histamine, but rather, competes with free histamine for binding at the H1-receptor sites, and competitively antagonizes the effects of histamine on H1-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Blockade of H1-receptors also suppresses the formation of oedema, flare, and pruritus that result from histaminic activity. Since dexchlorpheniramine binds to central and peripheral H1-receptors, sedative effects are likely to occur. Dexchlorpheniramine has high antihistaminic activity, moderate anticholinergic effects and minimal sedative effects.

Read about Dexchlorpheniramine
2 Phenylephrine
UNII 04JA59TNSJ - PHENYLEPHRINE HYDROCHLORIDE

Phenylephrine is a sympathomimetic agent with mainly direct effects on adrenergic receptors. It has predominantly alpha adrenergic activity and is without stimulating effects on the central nervous system. The sympathomimetic effect of phenylephrine produces vasoconstriction which in turn relieves nasal congestion.

Read about Phenylephrine
3 Sodium citrate
UNII 1Q73Q2JULR - SODIUM CITRATE, UNSPECIFIED FORM

Sodium citrate has no relevant pharmacodynamic activity other than that caused by its alkalinity (e.g. its gastric acid neutralising capacity). Sodium citrate is a non-particulate antacid for use by mouth to prior to general anaesthesia for caesarean section.

Read about Sodium citrate

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
R05CA10 Combinations R Respiratory system → R05 Cough and cold preparations → R05C Expectorants, excl. combinations with cough suppressants → R05CA Expectorants
Discover more medicines within R05CA10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: SG Health Sciences Authority Identifier(s): 11486P

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.